Pinnacle Oncology LLC Acquires Rights to Unique Radioprotector From the University of Chicago

BANNOCKBURN, Illinois, June 27, 2011 -

Pinnacle Oncology LLC, a subsidiary of Pinnacle Biologics Inc.
announced a wide ranging agreement with the University of Chicago
for the acquisition of its technology and intellectual property
rights for the development of a compound, amifostine, to prevent
genomic instability caused by a variety of sources of ionizing
radiation exposure including common Computer Tomography (CT)
scans.

Amifostine was initially developed by the United States Army to
protect military personnel from the toxic effects of radiation
exposure in the event of a nuclear war.  Animal studies
revealed that amifostine is very effective in protecting against
genomic instability and associated long term genomic damages
resulting from radiation exposure, such as from CT scans and other
diagnostic radiology and radiation oncology procedures that lead to
DNA damages, chromosomal aberrations and gene mutations, all of
which are associated with the cancer development processes.

“There are many potential uses for amifostine,” said David
Grdina, Professor of Radiation and Cellular Oncology at the
University of Chicago and inventor of the technology behind the
development of amifostine as a genomic stabilizing agent, “In
addition to protecting against genomic instability, somatic
mutagenesis and carcinogenesis, amifostine may also facilitate
protection against germ line mutations. These exposures can come
from a variety of sources including common diagnostic procedures,
such as computer tomography (CT) scans and more generalized
environmental exposures, as recently evidenced by the nuclear plant
accident in Japan.”  At present, none of these potential uses
have been approved by the FDA.

According to Viren Grover, Vice-Chairman at Pinnacle Biologics,
“It is clear that CT scans have revolutionized diagnostic imaging
and while they can provide great medical benefits, there is concern
that diagnostic CT scans may be responsible for elevating genomic
instability processes.  Over 70 million CT scans were
performed in the U.S. alone in 2007.  A study led by National
Institute of Cancer suggested that this may contribute to 29,000
new cancers each year along with 14,500 deaths.  Our proposal
is to develop amifostine for the prevention of genomic instability
in high risk individuals undergoing CT diagnostic procedures.”

About Pinnacle Biologics, Inc.

Pinnacle Biologics, a privately held bio-pharmaceutical company,
specializes in revitalizing healthcare therapies to fulfill their
true potential and to maximize favorable patient outcomes. This is
accomplished through licensing and acquisition of specialty
pharmaceuticals and medical devices. Our innovative approach to
opportunity analysis, business development, lifecycle management,
regulatory expertise and distribution leverage takes each product
to its highest degree of potential and maximum patient benefit.

About University of Chicago

The University of
Chicago is a private, nondenominational, culturally rich and
ethnically diverse coeducational institution of higher learning and
research. The University enrolls approximately 15,500 students
overall and in 2010 received $472 million in sponsored research
funding. Since 1892, UChicago scholars, scientists and educators
have made a profound and lasting impact upon the world. The
University’s Office of Technology and Intellectual Property,
UChicagoTech, manages the University’s dissemination of
intellectual property through commercial channels, including
inventions, software, and educational or research materials
involving new information technology.

Contact Information:

Viren Grover
Pinnacle Biologics, Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: +1-847-283-7690
F: +1-847-283-7695

href="www.pinnaclebiologics.com/">www.pinnaclebiologics.com

.